Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8182426 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL619199 | 1.00 | CA2 (0.58) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL7875753 | 0.84 | CA2 (0.59) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL12417023 | 0.83 | CA2 (0.54) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL31424266 | 0.83 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL9799039 | 0.83 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL9972148 | 0.83 | CA2 (0.50) | CA2ALDH1A1NPSR1CHRM2CHRM4 | |
| SCHEMBL12883057 | 0.81 | CA2 (0.49) | CA2ALDH1A1NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL9972151 | 0.81 | CA2 (0.49) | CA2ALDH1A1NPSR1MAPK1SMN1; SMN2 | |
| SCHEMBL22710100 | 0.81 | CA2 (0.49) | CA2ALDH1A1NPSR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-9249161-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249161-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249161-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140005169-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2014-01-02 | — | — | US | disclosed |
| US-20120264770-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2012075456-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075456-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20110053873-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-5264443-A | Psychotropic drugs, antidepressants and anxiolytic agents | DELALANDE S.A. (FR) | 1993-11-23 | — | — | US | disclosed |
| US-5235063-A | Acetal derivatives of 3-aryl-2-oxazolidine; antidepressants | DELALANDE S.A. (FR) | 1993-08-10 | — | — | US | disclosed |
| US-5196543-A | Antidepressants, tranquilizers | DELALANDE S.A. (FR) | 1993-03-23 | — | — | US | disclosed |
| US-5171747-A | Anxiolytic agents, antidepressants | DELALANDE S.A. (FR) | 1992-12-15 | — | — | US | disclosed |
| US-5036091-A | Psychotropic drugs | DELALANDE S.A. (FR) | 1991-07-30 | — | — | US | disclosed |
| US-5036090-A | Antidepressants | DELALANDE S.A. (FR) | 1991-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | CA2 3049/4885ALDH1A1 2921/4885NPSR1 4343/4885 |
| US-20140005169-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | CA2 3109/4885ALDH1A1 3348/4885NPSR1 4033/4885 |
| US-20120264770-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885 |
| US-20150315228-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | CA2 4668/4885ALDH1A1 3576/4885NPSR1 1224/4885 |
| US-20110053873-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4141/4885ALDH1A1 1554/4885NPSR1 4375/4885 |
| US-20120172321-A1 | HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | CA2 4094/4885ALDH1A1 1601/4885NPSR1 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.